CN102083986B - 不能在蚊子中复制的减毒重组甲病毒及其用途 - Google Patents

不能在蚊子中复制的减毒重组甲病毒及其用途 Download PDF

Info

Publication number
CN102083986B
CN102083986B CN200980110510.1A CN200980110510A CN102083986B CN 102083986 B CN102083986 B CN 102083986B CN 200980110510 A CN200980110510 A CN 200980110510A CN 102083986 B CN102083986 B CN 102083986B
Authority
CN
China
Prior art keywords
alphavirus
veev
ires
virus
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980110510.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102083986A (zh
Inventor
斯科特·C·韦弗
埃利亚·V·芙偌洛乌
叶莲娜·芙偌洛娃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN102083986A publication Critical patent/CN102083986A/zh
Application granted granted Critical
Publication of CN102083986B publication Critical patent/CN102083986B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN200980110510.1A 2008-01-24 2009-01-23 不能在蚊子中复制的减毒重组甲病毒及其用途 Expired - Fee Related CN102083986B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6222908P 2008-01-24 2008-01-24
US61/062,229 2008-01-24
PCT/US2009/000458 WO2009131604A2 (en) 2008-01-24 2009-01-23 Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof

Publications (2)

Publication Number Publication Date
CN102083986A CN102083986A (zh) 2011-06-01
CN102083986B true CN102083986B (zh) 2014-06-18

Family

ID=41217313

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980110510.1A Expired - Fee Related CN102083986B (zh) 2008-01-24 2009-01-23 不能在蚊子中复制的减毒重组甲病毒及其用途

Country Status (15)

Country Link
US (3) US8426188B2 (enExample)
EP (2) EP3085787B1 (enExample)
JP (1) JP5758632B2 (enExample)
KR (2) KR101668849B1 (enExample)
CN (1) CN102083986B (enExample)
AU (1) AU2009238667A1 (enExample)
CA (2) CA2713165C (enExample)
CO (1) CO6290702A2 (enExample)
IL (2) IL207167A (enExample)
MX (3) MX378503B (enExample)
MY (1) MY178870A (enExample)
NZ (2) NZ587502A (enExample)
SG (2) SG10201606111XA (enExample)
WO (1) WO2009131604A2 (enExample)
ZA (1) ZA201005943B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850977B2 (en) * 2007-06-21 2010-12-14 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
KR101668849B1 (ko) 2008-01-24 2016-10-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도
US8961995B2 (en) 2012-09-20 2015-02-24 Uab Research Foundation Methods and compositions for alphavirus replicons
WO2014052588A1 (en) 2012-09-27 2014-04-03 Research Development Foundation Attenuated chikungunya virus
CN111729077A (zh) 2013-03-14 2020-10-02 武田疫苗股份有限公司 减毒活甲病毒制剂的组合物和方法
CA3019536A1 (en) * 2016-03-31 2017-10-05 Takeda Vaccines, Inc. Live, attenuated alphavirus constructs and methods and uses thereof
BR112018074277A2 (pt) * 2016-05-27 2019-10-01 Univ Griffith vacina de alfavírus artrogênica
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
AU2019315577A1 (en) * 2018-08-03 2021-03-25 Uab Research Foundation Methods and compositions for alphavirus vaccine
CN109536464B (zh) * 2018-12-10 2022-06-10 中国科学院武汉病毒研究所 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
EP4085130A4 (en) 2019-12-31 2024-04-10 Elixirgen Therapeutics, Inc. TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2327189A1 (en) * 2000-12-21 2002-06-21 The Minister Of National Defence Novel dna-based vaccine against the encephalitis alphaviruses
CN1791678A (zh) * 2003-03-20 2006-06-21 阿尔法瓦克斯公司 改进的甲病毒复制子和辅助构建体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
AU2005256112B9 (en) 2004-07-30 2008-09-25 Blackberry Limited Method and system for coordinating device setting between a communications client and its host device
US7332322B2 (en) 2004-09-14 2008-02-19 Ilya Frolov Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof
CA2579507C (en) 2006-03-15 2017-06-13 Institut Pasteur Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
KR101668849B1 (ko) 2008-01-24 2016-10-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2327189A1 (en) * 2000-12-21 2002-06-21 The Minister Of National Defence Novel dna-based vaccine against the encephalitis alphaviruses
CN1791678A (zh) * 2003-03-20 2006-06-21 阿尔法瓦克斯公司 改进的甲病毒复制子和辅助构建体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
刘启良.序贯接种两种甲病毒减毒活疫苗产生的免疫干扰现象.《国外医学.预防.诊断.治疗用生物制品分册》.1998,第21卷(第06期), *

Also Published As

Publication number Publication date
CA2910235C (en) 2021-07-06
SG10201606111XA (en) 2016-09-29
IL232032A0 (en) 2014-05-28
JP5758632B2 (ja) 2015-08-05
NZ587502A (en) 2012-12-21
US20110052634A1 (en) 2011-03-03
US9580690B2 (en) 2017-02-28
KR101913790B1 (ko) 2018-12-28
EP3085787B1 (en) 2020-10-28
MX378503B (es) 2025-03-11
US20140010841A1 (en) 2014-01-09
CO6290702A2 (es) 2011-06-20
EP3085787A1 (en) 2016-10-26
US20170240919A1 (en) 2017-08-24
WO2009131604A3 (en) 2009-12-23
CA2713165C (en) 2015-12-29
IL207167A0 (en) 2010-12-30
CN102083986A (zh) 2011-06-01
KR101668849B1 (ko) 2016-10-24
AU2009238667A1 (en) 2009-10-29
WO2009131604A2 (en) 2009-10-29
KR20100106599A (ko) 2010-10-01
SG187513A1 (en) 2013-02-28
MX2019010530A (es) 2019-10-15
EP2250269A2 (en) 2010-11-17
MX2010007989A (es) 2010-12-21
CA2910235A1 (en) 2009-10-29
EP2250269A4 (en) 2012-01-04
KR20160124255A (ko) 2016-10-26
JP2011523347A (ja) 2011-08-11
MX367792B (es) 2019-09-05
US10533186B2 (en) 2020-01-14
CA2713165A1 (en) 2009-10-29
US8426188B2 (en) 2013-04-23
NZ603790A (en) 2014-08-29
EP2250269B1 (en) 2016-03-16
MY178870A (en) 2020-10-21
ZA201005943B (en) 2011-04-28
IL207167A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
CN102083986B (zh) 不能在蚊子中复制的减毒重组甲病毒及其用途
Paessler et al. Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic
Volkova et al. IRES-dependent replication of Venezuelan equine encephalitis virus makes it highly attenuated and incapable of replicating in mosquito cells
KR20090008193A (ko) 가감염성 플라비바이러스 및 이들의 용도
US20190106682A1 (en) Live, Attenuated Alphavirus Constructs and Methods and Uses Thereof
US8343506B2 (en) Chimeric chikungunya virus and uses thereof
CN101802179A (zh) 双组分基因组黄病毒及其应用
US9402890B2 (en) Methods and compositions for pseudoinfectious alphaviruses
AU2018229512B2 (en) Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
AU2014265084B2 (en) Attentuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
HK1230647A1 (en) Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof
AU2003299244A1 (en) Recombinant virus production for the manufacturing of vaccines
Attenuated Recombinant Sindbis/Venezuelan Equine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140618

Termination date: 20220123